Coherus Oncology (CHRS) news
Recent news
Coherus retains Oppenheimer to market remaining biosim assets
Coherus Oncology, Inc. (NASDAQ: CHRS) has engaged Oppenheimer & Co. Inc. as a joint bookrunner for a recent public offering, marking the latest step in the company’s capital-raising efforts. The offering, which closed recently, involved the sale of 28.6 million shares of common stock at $1.75 per…
AInvest Wire · Sep 23, 2026Coherus Oncology - Offering up to $50 mln of common stock - SEC filing
AInvest Wire · Aug 28, 2026Coherus Oncology - Enters sales agreement with Leerink Partners for common stock offering - SEC filing
Coherus Oncology, Inc. (NASDAQ: CHRS) has entered into a sales agreement with Leerink Partners for the potential offering of its common stock, according to recent SEC filings. While the specific terms of the agreement have not been disclosed, the move aligns with the company’s ongoing efforts to…
AInvest Wire · Aug 28, 2026Coherus Oncology - Terminates sales agreement with TD Securities (USA) on Aug 17, 2026 - SEC filing
Coherus Oncology, Inc. (NASDAQ: CHRS) has announced the termination of its sales agreement with TD Securities (USA) LLC, effective August 17, 2026, as disclosed in a recent SEC filing. The sales agreement, originally dated November 8, 2022, and amended on May 15, 2023, and September 11, 2023,…
AInvest Wire · Aug 28, 2026Coherus Oncology to issue biosimilar CVR special dividend
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.